David Elsley
Founder at CARDIOL THERAPEUTICS INC.
Net worth: 2 M $ as of 29/04/2024
David Elsley active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CARDIOL THERAPEUTICS INC. | Director/Board Member | 18/01/2017 | - |
| Chief Executive Officer | 18/01/2017 | - | |
| Founder | 18/01/2017 | - | |
| President | 18/01/2017 | - |
Career history of David Elsley
Former positions of David Elsley
| Companies | Position | Start | End |
|---|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Director/Board Member | 31/12/1989 | 22/10/2009 |
| Founder | 31/12/1989 | 22/10/2009 |
Training of David Elsley
| Richard Ivey School of Business | Masters Business Admin |
| University of Western Ontario | Masters Business Admin |
Statistics
International
| Canada | 5 |
Operational
| Director/Board Member | 2 |
| Founder | 2 |
| Masters Business Admin | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Stock Market
- Insiders
- David Elsley
- Experience
